Research Papers:
TSC-22 inhibits CSF-1R function and induces apoptosis in cervical cancer
Metrics: PDF 1537 views | HTML 3903 views | ?
Abstract
Min-Ji Cho1, Ji-Yeon Lee1, Min-Gwan Shin1, Hyun-Ji Kim1, Yu-Joung Choi1, Seung Bae Rho2, Boh-Ram Kim2, Ik Soon Jang3 and Seung-Hoon Lee1
1Department of Life Science, YongIn University, Yonginsi, Korea
2Research Institute, National Cancer Center, Goyang-si, Korea
3Division of Bioconvergence, Korea Basic Science Institute, Daejeon, Korea
Correspondence to:
Seung-Hoon Lee, email: [email protected]
Ik Soon Jang, email: [email protected]
Keywords: colony stimulating factor-1R; transforming growth factor-β-stimulated clone-22; cervical cancer; apoptosis
Received: February 16, 2017 Accepted: July 18, 2017 Published: August 16, 2017
ABSTRACT
Colony stimulating factor 1 receptor (CSF-1R) regulates the monocyte/macrophage system, which is an essential component of cancer development. Therefore, CSF-1R might be an effective target for anti-cancer therapy. The overexpression of transforming growth factor (TGF)-β stimulated clone-22 (TSC-22) inhibits cancer cell proliferation and induces apoptosis, and TSC-22 is emerging as a key factor in tumorigenesis. In this study, we discovered CSF-1R as a new interacting partner of TSC-22 and identified its elevated expression in cervical cancer cells. In particular, we found that TSC-22 interacted with the intracellular tyrosine kinase insert domain (539–749) of CSF-1R, which activates the AKT and ERK signaling pathways. This binding blocked AKT and ERK signaling, thereby suppressing the transcriptional activity of NF-κB. The overexpression of TSC-22 significantly decreased CSF-1R protein levels, affecting their autocrine loop. TSC-22 injected into a xenograft mouse model of human cervical cancer markedly inhibited tumor growth. The reduction of CSF-1R protein significantly suppresses cervical cancer cell proliferation and motility and induces apoptotic cell death. This association between TSC-22 and CSF-1R could be used as a novel therapeutic target and prognostic marker for cervical cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20296